Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

Published:2012-04 Issue:4 Volume:53 Page:632-634
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Damaj G.,Malard F.,Hulin C.,Caillot D.,Garidi R.,Royer B.,Marit G.,Stoppa A.M.,Banos A.,Morineau N.,Moreau P.,Fitoussi O.,Tiab M.,Moreau P.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.622422

Reference14 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Relapsed Multiple Myeloma

3. Bendamustine: Rebirth of an Old Drug

4. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines

5. Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

2. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial;British Journal of Haematology;2022-05-02

3. Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group;Journal of Clinical Medicine;2021-11-24

4. Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management;American Journal of Hematology;2021-06-26

5. Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent;Blood;2020-11-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3